Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Application of Nanotechnology in Skin Diseases
share announcement

Application of Nanotechnology in Skin Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 4497

Special Issue Editors

Dr. Renata Vidor Contri

E-Mail Website
Guest Editor
Departamento de Produção de Matéria-Prima, Unviersidade Federal do Rio Grande do Sul, Porto Alegre 90610-000, Brazil
Interests: nanotechnology; pharmaceutical technology, skin; cosmetics; dermatological products; topical products
Special Issues, Collections and Topics in MDPI journals
Dr. Irene Clemes Külkamp-Guerreiro

E-Mail Website
Guest Editor
Departamento de Produção de Matéria-Prima, Unviersidade Federal do Rio Grande do Sul, Porto Alegre 90610-000, Brazil
Interests: nanotechnology; pharmaceutical technology, skin; cosmetics; pediatric products
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Skin disorders or diseases involving skin infection, skin hyperpigmentation, inflammatory conditions or cell hyperproliferation conditions are extremely common worldwide, and often result in suffering and stigma for affected people. The topical treatment of such diseases by applying drugs and active substances on the affected area provides a more convenient treatment, with a local effect and lower probability of systemic side effects. However, this route of administration has limitations, which can be overcome by the use of nanotechnology. Nanotechnology used in topical formulations can increase skin permeation and improve drug delivery to skin structures such as follicles, creating a deposit of the substance in the skin. In addition to improving the drug/active effect, the use of nanotechnology can promote dose reduction, decrease side effects, protect the substance from degradation, and improve the product stability and sensorial properties. Therefore, we invite research articles, reviews, communications and case studies related to the application of nanotechnology in skin diseases including, but not limited to, mycoses, bacterial infections, melasma, skin hyperpigmentation, acne, dermatitis, psoriasis, rosacea and skin cancer.

Dr. Renata Vidor Contri
Dr. Irene Clemes Külkamp-Guerreiro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • nanocosmetics
  • nanoformulation
  • nanoparticles
  • nanoemulsion
  • liposomes
  • cubosomes
  • micelles
  • skin diseases
  • skin disorders
  • mycoses
  • infection
  • hyperpigmentation
  • melasma
  • acne
  • dermatitis
  • skin cancer
  • psoriasis
  • rosacea

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2037 KiB  
Article
Development of a Clioquinol Nanocarrier as a New, Promising Option for the Treatment of Dermatomycosis
by Simone Jacobus Berlitz, Paula Reginatto, Gabriella da Rosa Monte Machado, Alexandre Meneghello Fuentefria, Fernando Dal Pont Morisso, Renata Vidor Contri and Irene Clemes Külkamp-Guerreiro
Pharmaceutics 2023, 15(2), 531; https://doi.org/10.3390/pharmaceutics15020531 - 04 Feb 2023
Cited by 1 | Viewed by 1503
Abstract
Dermatomycosis is a common fungal infection, and its treatment is limited by few antifungal agents. Clioquinol (CQ) is an antiparasitic agent that has been studied for new uses, such as antifungal and antiviral applications. CQ was incorporated into a lipid-based nanocarrier as a [...] Read more.
Dermatomycosis is a common fungal infection, and its treatment is limited by few antifungal agents. Clioquinol (CQ) is an antiparasitic agent that has been studied for new uses, such as antifungal and antiviral applications. CQ was incorporated into a lipid-based nanocarrier as a new, promising option for dermatomycosis. This study aimed to develop a CQ-loaded lipid-based nanocarrier for cutaneous application and to evaluate its antifungal activity. CQ-loaded nanoformulation (LBN-CQ) was developed using the ultrasonication method, and the particle size, polydispersity index (PDI), pH, zeta potential, and drug content were monitored for 45 days. To evaluate antifungal activity, broth microdilution and a time-kill assay were performed. LBN-CQ presented a particle size of 91 ± 3 nm and PDI of 0.102 ± 0.009. The zeta potential and pH values were −9.7 ± 2.0 mV and 6.0 ± 0.1, respectively. The drug content was 96.4 ± 2.3%, and the encapsulation efficiency was 98.4%. LBN-CQ was able to reduce the minimum inhibitory concentration (MIC) in a 2-fold or 4-fold manner in most of the tested strains. Additionally, LBN-CQ presented stable fungistatic action that was not concentration- or time-dependent. In conclusion, the developed CQ-loaded nanocarrier is a promising treatment for skin fungal infections and a promising candidate for future randomized clinical trials. Full article
(This article belongs to the Special Issue Application of Nanotechnology in Skin Diseases)
►▼ Show Figures

Figure 1

16 pages, 2834 KiB  
Article
Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma
by Júlia Capp Zilles, Larissa Pedron Duarte, Thaís Carine Ruaro, Aline Rigon Zimmer, Irene Clemes Kulkamp-Guerreiro and Renata Vidor Contri
Pharmaceutics 2023, 15(2), 468; https://doi.org/10.3390/pharmaceutics15020468 - 31 Jan 2023
Cited by 4 | Viewed by 2316
Abstract
Melasma is a hard-to-treat hyperpigmentation disorder. Combined incorporation of kojic dipalmitate (KDP), the esterified form of kojic acid, and rosehip oil, an oil with antioxidant and skin-regenerating properties, into nanocarrier systems appears to be a suitable strategy to develop high-performance formulations. A high-energy [...] Read more.
Melasma is a hard-to-treat hyperpigmentation disorder. Combined incorporation of kojic dipalmitate (KDP), the esterified form of kojic acid, and rosehip oil, an oil with antioxidant and skin-regenerating properties, into nanocarrier systems appears to be a suitable strategy to develop high-performance formulations. A high-energy method (Ultra-Turrax®) was used to develop nanoemulsions containing up to 2 mg/mL KDP, 5% rosehip oil, and 7.5% surfactant. Formulations were characterized regarding droplet size, size distribution, pH, density, morphology, KDP content, incorporation efficiency, and stability under different temperature conditions. A scale-up study was conducted. Skin permeation, antioxidant potential, and tyrosinase inhibitory activity were assessed in vitro. Cell viability studies were also performed. Results showed that nanoemulsions containing 1 and 2 mg/mL KDP had incorporation efficiencies greater than 95%, droplet size smaller than 130 nm, suitable size distribution, zeta potential of approximately −10 mV, and good stability over 30 days of refrigerated storage. The nanoemulsion containing 1 mg/mL KDP was chosen for further evaluation because it had lower nanocrystal formation, greater scale-up feasibility and allowed KDP permeation up to the epidermis similarly than observed for 2 mg/mL KDP. This formulation (1 mg/mL KDP) showed antioxidant and depigmenting efficacy, close to that of 1 mM ascorbic acid. No cytotoxicity was observed in formulations concentrations ranging from 0.06% to 1%. Full article
(This article belongs to the Special Issue Application of Nanotechnology in Skin Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop